Andrew Epstein

Cooley advised a syndicate of globally recognized private and public investors in connection with the management-led majority stake acquisition of HistoSonics, the developer of the Edison Histotripsy System and novel histotripsy therapy platform, valuing the company at approximately $2.25 billion.

Cooley advised Inmagene Biopharmaceuticals, a privately held, global clinical-stage biotechnology company developing novel therapeutics for immunological and inflammatory diseases, on its definitive merger agreement with Ikena Oncology (Nasdaq: IKNA).

Cooley advised Capstan Therapeutics, a clinical-stage biotechnology company with a mission to multiply therapeutic possibilities for patients through targeted in vivo RNA technologies, on its definitive agreement to be acquired by AbbVie.

Cooley advised SoftEye, a San Diego-based company developing specialized chips, cameras, software and algorithms for use in smart glasses, on its sale to TDK Corporation, a Tokyo-based global leader in advanced electronic solutions designed for a smarter, more connected world.

Cooley advised Tenable, an exposure management company, on its definitive agreement to acquire Apex Security, an innovator in securing the rapidly expanding artificial intelligence attack surface.